Dr. Reddy's Laboratories Share Price

NSE: DRREDDY

₹ 1,151.70

-₹14.60 (-1.25%)

Last updated 24 Jul, 2026, 15:58 IST

Dr. Reddy's Laboratories Share Price Today

As of 24 Jul 2026, Dr. Reddy's Laboratories share price is ₹1,151.70. The stock opened at ₹1,147.00, compared to its previous close of ₹1,166.30. During today's trading session, Dr. Reddy's Laboratories share price moved in the range of ₹1,131.40 to ₹1,166.30, with an average price of ₹1,148.85 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,101.00 and a high of ₹1,414.90. On the performance front, Dr. Reddy's Laboratories share price has declined by 5.61% over the last six months and is down 6.50% on a year-on-year basis.

₹1,131.40

1.25% down today

₹1,166.30

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 177.07% QoQ

Latest Earning

Net Profit TrendUp by 96.84% QoQ

Latest Earning

Revenue TrendUp by 5.39% QoQ

Stock Performance

UnderperformingUnderperforming Nifty by 2.28 % in last 1 year

Shareholding Pattern

DIIDII increased stake by 6.03%

Shareholding Pattern

FIIFII decreased stake by 3.05%

Dr. Reddy's Laboratories Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹4,50,622-₹49,378 (-9.88%)

3 Year

₹5,10,460+₹10,460 (+2.09%)

5 Year

₹6,11,144+₹1,11,144 (+22.23%)

₹1,049.70₹1,282.90

Circuit Low

Circuit High

₹1,101.00₹1,414.90

52-Week Low

52-Week High

Circuit

₹1,049.70

₹1,282.90

52-week

₹1,101.00

₹1,414.90

Mkt Cap Cr

97,364.90

P/E

30.58

P/B

2.56

ROE

11.07%

D/E

0.18

ROCE

12.54%

Div. Yield

0.69%

EPS(TTM)

38.68

Turnover

0.41

EV/EBITDA

15.68

Net Margin

15.68%

Op. Margin

27.31%

ROA

5.48%

Quick Ratio

1.22

Curr. Ratio

3.28

Mkt Cap Cr

97,364.90

P/E

30.58

P/B

2.56

ROE

11.07%

D/E

0.18

ROCE

12.54%

Div. Yield

0.69%

EPS(TTM)

38.68

Turnover

0.41

EV/EBITDA

15.68

Net Margin

15.68%

Op. Margin

27.31%

ROA

5.48%

Quick Ratio

1.22

Curr. Ratio

3.28

Based on fundamentals, this stock's

Performance

Very Poor

Dr Reddy's Labs has not beaten FD return of 7%

Valuation

Overvalued

Dr Reddy's Labs appears overvalued compared to its peers

Earnings

Good

Dr Reddy's Labs revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,68,842.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,05,607.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.45	16.70%	10.19	0.20%	0.97	13.72
Biocon	70,908.00	151.62	1.71	1.34%	0.10	3.76%	2.16	0.14%	0.09	0.27

Dr. Reddy's Laboratories Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹33,700.20	₹32,643.90	₹28,011.10	₹24,669.70
Other Income	₹1,358.40	₹1,097.30	₹894.30	₹1,055.50
Total Revenue	₹35,058.60	₹33,741.20	₹28,905.40	₹25,725.20
Total Expenses	₹29,679.30	₹26,083.40	₹21,719.10	₹19,713.70
Profit Before Tax	₹5,392.70	₹7,679.50	₹7,201.00	₹6,048.50
Tax	₹1,235.10	₹1,954.30	₹1,623.10	₹1,541.20
Profit After Tax	₹4,157.60	₹5,725.20	₹5,577.90	₹4,507.30
EPS - Basic	₹50.41	₹67.89	₹67.04	₹271.47
EPS - Diluted	₹50.35	₹67.79	₹66.92	₹270.90

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹5,392.70	₹7,679.50	₹7,201.00	₹6,048.50
Income before WC changes	₹8,100.90	₹9,641.00	₹8,566.20	₹7,744.40
Change in Assets	-₹1,532.30	-₹2,303.60	-₹2,649.90	-₹840.60
Change in Liabilities	₹457.70	-₹695.30	₹631.70	₹55.10
Change in WC	-₹1,074.60	-₹2,998.90	-₹2,018.20	-₹785.50
Cash flow from Operations	₹5,673.70	₹4,642.80	₹4,543.30	₹5,887.50
Cash flow from Investing	-₹6,549.30	-₹5,807.70	-₹4,028.30	-₹4,137.30
Cash flow from Financing	₹829.00	₹1,891.10	-₹376.30	-₹2,686.10
Total Cash Flow	-₹46.60	₹726.20	₹138.70	-₹935.90
Cash (Start of the year)	₹1,459.30	₹710.70	₹577.90	₹1,485.20
Cash (End of the year)	₹1,536.80	₹1,459.30	₹710.70	₹577.90

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹27,944.10	₹24,408.50	₹14,058.50	₹11,859.60
Current Assets	₹30,179.30	₹25,018.10	₹24,805.30	₹20,425.50
Total Assets	₹58,123.40	₹49,426.60	₹38,863.80	₹32,285.10
Current Liabilities	₹16,747.40	₹13,033.80	₹9,588.00	₹8,572.10
Net Current Asset	₹13,431.90	₹11,984.30	₹15,217.30	₹11,853.40
Non-Current Liabilities	₹3,145.10	₹2,465.40	₹1,021.00	₹426.90
Equity Capital	₹38,230.90	₹33,927.40	₹28,254.80	₹23,286.10
Total Equity & Liabilities	₹58,123.40	₹49,426.60	₹38,863.80	₹32,285.10

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹20,532.80	₹23,115.40	₹19,483.80	₹16,962.50
Other Income	₹1,689.60	₹1,003.40	₹862.30	₹591.30
Total Revenue	₹22,222.40	₹24,118.80	₹20,346.10	₹17,553.80
Total Expenses	₹17,971.10	₹16,882.90	₹14,554.80	₹13,687.80
Profit Before Tax	₹4,251.30	₹7,235.90	₹5,791.30	₹3,866.00
Tax	₹1,031.60	₹1,886.50	₹1,449.30	₹1,253.20
Profit After Tax	₹3,219.70	₹5,349.40	₹4,342.00	₹2,612.80
EPS - Basic	₹38.68	₹64.22	₹52.19	₹157.37
EPS - Diluted	₹38.64	₹64.13	₹52.09	₹157.03

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹4,251.30	₹7,235.90	₹5,791.30	₹3,866.00
Income before WC changes	₹4,742.30	₹8,050.30	₹6,393.30	₹4,911.80
Change in Assets	₹999.10	-₹2,179.10	-₹1,558.00	₹556.80
Change in Liabilities	-₹133.60	-₹59.80	-₹66.10	₹367.00
Change in WC	₹865.50	-₹2,238.90	-₹1,624.10	₹923.80
Cash flow from Operations	₹4,660.50	₹4,225.00	₹3,449.70	₹5,052.90
Cash flow from Investing	-₹5,784.70	-₹5,697.60	-₹3,430.30	-₹3,447.60
Cash flow from Financing	₹1,116.80	₹1,590.70	₹68.10	-₹2,696.90
Total Cash Flow	-₹7.40	₹118.10	₹87.50	-₹1,091.60
Cash (Start of the year)	₹319.70	₹201.40	₹112.30	₹1,159.50
Cash (End of the year)	₹337.50	₹319.70	₹201.40	₹112.30

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹25,078.90	₹21,787.90	₹12,543.40	₹11,586.50
Current Assets	₹18,523.20	₹16,503.00	₹17,815.90	₹13,788.30
Total Assets	₹43,602.10	₹38,290.90	₹30,359.30	₹25,374.80
Current Liabilities	₹11,142.50	₹8,651.80	₹5,538.10	₹4,439.70
Net Current Asset	₹7,380.70	₹7,851.20	₹12,277.80	₹9,348.60
Non-Current Liabilities	₹1,094.00	₹782.50	₹580.40	₹460.90
Equity Capital	₹31,365.60	₹28,856.60	₹24,240.80	₹20,474.20
Total Equity & Liabilities	₹43,602.10	₹38,290.90	₹30,359.30	₹25,374.80

* All values are in INR Crore

Qty

Bid

Ask

Qty

Bid Total: 0

Ask Total: 0

Buy orders: 0%

Sell orders: 0%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bearish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

27.38

Bearish

ATR (14)

35.96

Neutral

STOCH(9,6)

44.09

Neutral

STOCH RSI (14)

Bullish

ADX(9)

49.25

Bearish

UO(9)

44.14

Neutral

ROC(12)

-13.9

Bearish

WillR(14)

-76.84

Neutral

Period

Simple value

Exponential vaue

1197.88

1194.71

10D

1216.83

1220.87

20D

1282.62

1251.75

50D

1289.59

1275.37

100D

1282.8

1275.91

About Dr. Reddy's Laboratories

ISIN

INE089A01031

Sector Market Cap

₹ 97,364.9 Cr

Dr. Reddy's Laboratories is an Indian pharmaceutical company that was founded in 1984 by Kallam Anji Reddy. Headquartered in Hyderabad, the company produces over 190 medications and over 60 active pharmaceutical ingredients (APIs).

The market capitalisation of Dr. Reddy's Laboratories Limited was ₹97,400 crore as of January 4, 2024. The share price of Dr. Reddy's has gained over 10% in the last three years

Business Operations

Dr. Reddy's Laboratories has been an active player in the pharmaceutical sector for more than 20 years. Its expertise lies in Active Pharmaceutical Ingredients (API), boasting a diverse portfolio. They specialise in manufacturing generic medicines with operations in India, Russia, US and Germany.

The company also engages in proprietary products, biologics business and unique formulations conducted primarily in the US. It has introduced Grafeel (Filgrastim), a drug used to fight infections after chemotherapy, and Reditux (Rituximab), an ant-cancer drug.

Dr. Reddy's produces a diverse range of intricate APIs and holds over 1,150 drug master files covering key therapy areas like oncology, cardiovascular, central nervous system and anti-diabetes. With 22 manufacturing facilities worldwide, the company ensures top-quality output and timely supply to markets. Its expertise in Active Pharmaceutical Ingredients (API) spans 8 manufacturing units globally.

The company’s largest manufacturing facility is located in Bachupally, Hyderabad. As of FY22, it has filed 1,071 patents and published over 1,000 papers.

Central to its R&D excellence is the Integrated Product Development Organisation (IPDO) situated in Hyderabad. This extensive campus hosts multiple laboratories, including the latest addition, a nutraceutical R&D centre. These cutting-edge labs are powered by a diverse team of scientists recruited from leading institutions worldwide.

The dedicated efforts of Dr. Reddy's in product development support a portfolio exceeding 1,000 products. The pharma giant has an R&D team comprising over 150 doctorates.

The company is focused on research and has a strong team of over 3,000 scientists in 8 R&D facilities. As of March 31, 2023, Dr. Reddy's is powered by a workforce of 25,498 permanent employees and workers in 74 countries.

The business of Dr. Reddy's Laboratories in branded generics thrives not only in India but also in emerging markets globally. Its branded products reach over 30 countries, spanning Asia, Africa, Australia, New Zealand, Russia, Romania, China and Latin America.

The company's growth rate has doubled in the past four years. It has reached a prominent position in crucial therapy areas like oncology, gastroenterology, allergy, diabetes and pain management. Within its Indian operations, it structures its business according to therapies, managing over 300 brands. Its extensive reach to healthcare professionals is facilitated by a field force comprising approximately 7,500 members.

Dr. Reddy's Laboratories Financial Highlights

Revenue: Dr. Reddy's Laboratories reported revenue of ₹35,058.60 crore in FY26 vs ₹33,741.20 crore in FY25. It showed an increase of 3.90% on a yearly basis.
Operating Profit: Dr. Reddy's Laboratories reported an operating profit of ₹5,392.70 crore in FY26 vs ₹7,679.50 crore in FY25. It showed a decrease of 29.78% on a year-on-year basis.
Net Profit: Dr. Reddy's Laboratories reported a net profit of ₹4,157.60 crore in FY26 vs ₹5,725.20 crore in FY25. It showed a decrease of 27.38% on a yearly basis.

Dr. Reddy's Laboratories Quarterly Result Highlights

Dr. Reddy's Laboratories reported revenue of ₹8,454.50 crore in Jun 2026, compared with ₹8,021.80 crore in Mar 2026, representing an increase of 5.39% on a quarter-on-quarter (QoQ) basis.
Dr. Reddy's Laboratories reported an operating profit of ₹553.30 crore in Jun 2026, compared with ₹199.70 crore in Mar 2026, representing an increase of 177.07% on a quarter-on-quarter (QoQ) basis.
Dr. Reddy's Laboratories reported a profit of ₹435.60 crore in Jun 2026, compared with ₹221.30 crore in Mar 2026, reflecting an increase of 96.84% on a QoQ basis.
The earnings per share (EPS) of Dr. Reddy's Laboratories stood at ₹50.41 during Jun 2026.